( THE WOODLANDS Texas--(BUSINESS WIRE)--...)Opexa Advances Monocyte Derived Islet Technology to Proof of,Principle in stz-induced NOD/SCID Mice,Health

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 27, 2007 - Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, presented poster presentations at the 5th International Society for Stem Cell Research Annual Meeting (ISSCR) in Cairns, Queensland, Australia from June 17-20 and at the 13th Annual Meeting of the International Society for Cellular Therapy (ISCT) in Sydney, Australia from June 24-27. The two presentations covered recent research from Opexa's innovative adult stem cell program regarding the development of adult monocyte-derived islets, as beta-cell replacement therapy for diabetes mellitus.

The first presentation was made by Opexa's director of stem cell research, Glenn Winnier, Ph.D. at the ISSCR Annual Meeting and described the differentiation of adult monocyte-derived stem cells (MDSCs) to generate pancreatic endocrine cell clusters known as monocyte-derived islets (MDIs). MDIs express pancreatic specific factors as well as hormones insulin, glucagons and somatostatin in physiological proportions. These studies also demonstrated that MDIs function in a glucose responsive manner when transplanted into diabetic animals. Study animals demonstrate a prolonged reduction (greater than 60 days) in blood glucose levels when MDIs were transplanted under the kidney capsule of stz-induced NOD/SCID mice.

The second presentation, also made by Dr. Winnier, was presented at the ISCT Annual Meeting in Sydney, Australia. The Company's recent adult stem cell research has demonstrated the successful generation of MDIs from insulin-dependent type 1 and type 2 diabetics. These insulin producing islet-like clusters express insulin, glucagon and somatostatin characteristic hormones found in pancreatic islets and function in a glucose responsive manner.

Dr. Winnier commented, "The development of adult MDIs from healthy subjects and the demonstration
'"/>

Page: 1 2 3
Related medicine technology :

1. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
2. Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
3. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
4. Monitoring Patient Glucose Levels: New Advances in software make it easier
5. New Advances in Gastric Diagnostics: Smaller is Better
6. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
7. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
8. Use of Sequenoms MassARRAY System Leads to Significant Scientific Advances in Understanding Cancer, Diabetes and Drug-Resistant Malaria
9. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
10. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
11. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak